

Cumulative Index 2004

Volume 22

February	ATRIAL FIBRILLATION, pages 1-170
May	CONTRAST ECHOCARDIOGRAPHY, pages 171-326
August	PULMONARY VASCULAR DISEASE, pages 327-484
November	DIABETES AND CARDIOVASCULAR DISEASE, pages 485-602

Note: Page numbers of article titles are in **boldface** type.

A

- Acute pulmonary embolus
 - echocardiography in, 385-389
- Alternate line phase
 - in low-myocardial infarction detection, 185-186
- Amiodarone
 - for atrial fibrillation, 23-24
 - for heart rate control in atrial fibrillation, 41
 - in prevention of postoperative atrial fibrillation, 162-163
- Angiography
 - conventional
 - in pulmonary embolism, 378
 - in pulmonary vascular disease, 375
 - in CTEPF diagnosis, 458-459
 - pulmonary
 - in cardiac catheterization in pulmonary hypertension, 405-408
 - in CTEPF diagnosis, 458
- Angioscopy
 - pulmonary
 - in cardiac catheterization in pulmonary hypertension, 408-412
- Antiarrhythmic drug therapy
 - for atrial fibrillation, **21-34**. See also *Atrial fibrillation, antiarrhythmic drug therapy for*.
- Anticoagulation
 - for atrial fibrillation, **47-62**. See also *Atrial fibrillation, anticoagulation for*.
 - electrical cardioversion and
 - of atrial fibrillation, 110-111
 - for postoperative atrial fibrillation, 164
- Antiplatelet agents
 - anticoagulation and
 - for atrial fibrillation, 51-52
 - for atrial fibrillation, 50-51
- Antithrombotic therapy
 - for atrial fibrillation
 - guidelines for, 53
- Apoptosis
 - imaging of, 294
 - inhibited
 - in pulmonary artery smooth muscle cells, 420-421
- Arterial stiffness
 - exercise and, 573-574
 - in type 2 diabetics with hypertension, 573
- Arteriography
 - coronary
 - in cardiac catheterization in pulmonary hypertension, 412
 - pulmonary
 - in acute pulmonary embolism diagnosis, 356-357
- Artery patency
 - infarct-related
 - assessment of, 255
- Artifact(s)
 - LVO
 - on contrast echocardiography, 205
- Aspirin
 - for atrial fibrillation, 50-51
 - efficacy of, 51

Atherosclerosis

coronary

- in diabetes mellitus, **527-540**. See also *Diabetes mellitus, coronary atherosclerosis in*.

Atherosclerotic plaque

targeted imaging of

- contrast agents in, 292-293

Atrial fibrillation

animal models of, 9-10

antiarrhythmic drug therapy for, **21-34**

acute treatment, 26-29

amiodarone, 23-24

class IA agents, 24-25

class IC agents, 21-22

dofetilide, 23

inpatient *vs.* outpatient initiation of, 25-26

sotalol, 22-23

in special circumstances, 29-30

anticoagulation for, **47-62**adjusted-dose *vs.* low-intensity, 50

antiplatelet agents in, 50-52

aspirin in, 50-51

efficacy of, 51

bleeding complications of, 53-55

cost-effectiveness of, 56-57

decision-making in, 56-57

intensity of, 55

management of, 56

new agents in, 57-58

sinus rhythm restoration and, 57

antithrombotic therapy in

guidelines for, 53

atrial remodeling and reverse remodeling in, 12-13

cardiac conditions and, 1-3

catheter ablation therapy for, **129-147**

clinical trials of

results of, 139

complications of, 139-143

future directions in, 143

patient selection for, 138-139

techniques for, 131-138

activation mapping, 131-132

atrial substrate modification, 136-138

basket and noncontact catheter mapping, 132-134

linear ablation, 137-138

pulmonary vein isolation, 134-136

extraostial, 136-137

intracardiac

echocardiography-guided,

134-135

map-guided, 135-136

conventional pacing in, 80-83

in AV junction ablation, 81-82

described, 1

device therapy for, **71-86**. See also *Device therapies, for atrial fibrillation*.

diagnosis of, 4-6

early reinitiation of

implantable devices and, 95-97

electrical cardioversion of, **103-113**

adverse effects of, 110-111

anticoagulation and, 110-111

drugs in, 107-110

energy selection in, 103-105

internal, 110

refractory cases of, 107-110

technique of, 105-107

waveforms in, 103-105

epidemiology of

guiding lessons from, **1-8**

seasonal variations in, 3

gender predilection for, 1

heart rate control in

pharmacological agents in, **35-45**

amiodarone, 41

beta blockers, 40-41

calcium channel blockers, 37-40

digoxin, 37

flecainide, 41

importance of, 36

propafenone, 41

selection of, 36-37

sotalol, 41

hypertension and, 6

in hypertrophic cardiomyopathy

antiarrhythmic drug therapy for, 30

implantable devices for

clinical use of

issues related to, 94-95

described, 87-89

device therapies, 93-94

diagnostic features of, 94

efficacy of, 93-94

dual chamber detection algorithm in, 89-92

electrode configuration in, 92-93

electromechanical remodeling and, 97

future prospects for, **87-101**

implantable atrioventricular implantable

cardioverter defibrillator, 88-89

quality of life with, 98

stand-alone implantable atrial defibrillator, 88

initiation of, 10-12

literature review of, 35-36
making order out of chaos in, 13
management of
 chronic maintenance, 21-26
mechanisms of
 basic, 9-20
 focal sources in, 15-18
 multiple wavelets, 13-15
 pulmonary veins, 15-18
 therapeutic implications of, 87
"mother rotor" theory in, 15
newer pacing algorithms in, 82-83
newer therapeutic algorithms in, 82-83
pathophysiology of, 129-131
in post-cardiac surgery setting, **161-168**
 epidemiology of, 161-162
 management of, 164-166
 anticoagulation in, 164
 rate control in, 164
 restoration of sinus rhythm in, 164-165
 prevention of
 atrial pacing in, 163-164
 pharmacologic agents in, 162-163
 treatment algorithm for, 165-166
predictors of, 3-4
during pregnancy
 antiarrhythmic drug therapy for, 29
prevalence of, 1
prevention of
 atrial pacing in, 71-78
 after cardiac surgery, 75-78
 alternative site, 78
 effect on atrial substrate suppression of
 compensatory pause, 74
 multi-site pacing, 74-75
 reducing dispersion of refractoriness,
 74-75, 78
rate and rhythm control in, **35-41**
 advantages of, 35-36
 trials comparing, 36-39
rate *vs.* rhythm control in
 disadvantages of, 35-36
risk factors for, 3-4
risk-stratification for, 52-53
screening for, 5-6
stroke prevention in
 in clinical practice, 56
 oral anticoagulants for
 efficacy of, 47-50
surgical treatment of
 advances in, **149-159**
 indications for, 155-157
 Maze procedure, 149-151

 strategies for, 155-157
 termination of
 atrial pacing in, 78-80
 transesophageal echocardiography in,
 115-128
 future directions in, 125-126
 type of, 35
 with ventricular pre-excitation
 antiarrhythmic drug therapy for, 29

Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) trial, 21

Atrial flutter
 stroke associated with
 risk factors for, 58

Atrial pacing
 after cardiac surgery, 75-78
 in atrial fibrillation prevention, 71-78.
 See also *Atrial fibrillation, device therapy
 for, for atrial fibrillation.*
 in atrial fibrillation termination, 78-80
 in prevention of postoperative atrial
 fibrillation, 163-164

B

Bernoulli equation
 in estimation of pulmonary arterial pressure,
 384-385

Beta blockers
 for heart rate control in atrial fibrillation,
 40-41

Biphasic waveform
 studies of
 in electrical cardioversion of atrial
 fibrillation, 104-105

Bleeding
 anticoagulation for atrial fibrillation and,
 53-55

Blood flow
 myocardial
 regulation of
 myocardial blood volume in,
 223-227

Blood flow reserve
 coronary
 reduced
 implications of, 227-228

Blood pressure
 management of
 in diabetic cardiomyopathy, 559-560

Blood volume
myocardial
in myocardial blood flow regulation,
223-227

Body composition
exercise and, 575-576

Bone morphogenic protein receptor type II gene
mutations
in primary pulmonary hypertension, 421-422

C

Calcium channel blockers
for heart rate control in atrial fibrillation,
37-40
for pulmonary arterial hypertension, 445

Capillary resistance
during hyperemia, 227-228

Cardiac abnormalities
functional
diabetic cardiomyopathy and, 557-558

Cardiac catheterization
in pulmonary hypertension, 401-415. See also
*Pulmonary hypertension, cardiac
catheterization in.*
right-heart
in CTEPH diagnosis, 458
in pulmonary arterial hypertension
diagnosis, 443
in pulmonary hypertension diagnosis, 371

Cardiac conditions
atrial fibrillation and, 1

Cardiac surgery
atrial pacing after, 75-78

Cardiomyopathy(ies)
diabetic, 553-559. See also *Diabetic
cardiomyopathy.*
dilated
MCE in
ad, 270-274
hypertrophic
antiarrhythmic drug therapy for, 30
MCE in, 274-279. See also *Hypertrophic
cardiomyopathy, MCE in.*
ischemic
chronic
MCE in, 269-282. See also *Myocardial
contrast echocardiography (MCE).*
nonischemic
chronic

MCE in, 269-282. See also *Myocardial
contrast echocardiography (MCE).*

Cardiovascular disease
in diabetes mellitus
pathophysiology of
endothelial dysfunction in, 505-509. See
also *Diabetes mellitus, cardiovascular
disease in, pathophysiology of,
endothelial dysfunction in.*
diabetes mellitus and, 485-504. See also
*Diabetes mellitus, type 2, cardiovascular
diseases and.*
in the elderly
pathophysiologic factors in, 542
in type 2 diabetics with hypertension
exercise training effects on, 569-586. See
also *Diabetes mellitus, type 2,
hypertension with, cardiovascular disease
in, exercise training effects on.*

Cardiovascular system
type 2 diabetes mellitus effects on, 569

Cardioversion
anticoagulation for, 57-58
drugs in facilitation of, 108-110
electrical
of atrial fibrillation, 103-113. See *Atrial
fibrillation, electrical cardioversion of.*
internal, 110
transesophageal echocardiography-guided,
121-125

Carotid ultrasound imaging, 315-318
intimal medial thickness in, 316
plaque lucency in, 315-316
plaque neovascularization in, 317-318

Catheter ablation therapy
for atrial fibrillation, 129-147. See also *Atrial
fibrillation, catheter ablation therapy for.*

Catheterization
cardiac. See *Cardiac catheterization.*

Chest radiography
in acute pulmonary embolism diagnosis,
355-356
in CTEPH, 456
in pulmonary arterial hypertension, 379
in pulmonary embolism, 377-378

Chronic pulmonary hypertension
echocardiography in, 390-396. See also
*Pulmonary hypertension, chronic,
echocardiography in.*

- Chronic thromboembolic pulmonary
hypertension (CTEPH), 380-381, **453-466**
classification of, 473-474
clinical manifestations of, 468
clinical presentation of, 455-459
diagnosis of, 468-469
echocardiography in, 395
evaluation of, 455-459
historical background of, 453-454
incidence of, 467-468
natural history of, 454-455, 467-468
pulmonary thromboendarterectomy surgery
for, **467-478**
guiding principles of, 471
outcome of
prediction of, 473-474
patient selection for, 469-471
results of, 474-476
technique of, 471-473
treatment of
surgical, 459-463
patient selection for, 459-460
preoperative management in,
459-460
pulmonary thromboendarterectomy,
460-463
- Circulation
coronary
anatomy of, 221-223
- Coagulation cascade
diabetes mellitus and, 514-515
- Coagulopathy
in diabetes mellitus
platelet function and fibrinolytic system
interactions with, **511-526**
- Coherent contrast imaging
in low-myocardial infarction detection,
185-186
- Computed tomography (CT)
in CTEPH, 456
in pulmonary arterial hypertension, 379
in pulmonary embolism, 378-379
in pulmonary vascular disease, 375-376
spiral
in acute pulmonary embolism, 357
- Congenital heart disease
pulmonary arterial hypertension and, 333
- Connective tissue disease
pulmonary arterial hypertension and,
332-333
- Contrast agents
in contrast echocardiography in left ventricular
function assessment, 212
microbubble, 223
for echocardiography, **171-180**. See also
*Microbubble contrast agents, for
echocardiography*.
targeting with
by surface ligands, 288-294
for vascular imaging, **315-322**
- Contrast echocardiography
clinical utility of, 212-213
in ICU
clinical utility of, 212-213
in laboratory
clinical indications for, 205
implementation of, **199-209**
artifacts in, 205
challenges in, 204-205
economic considerations in, 206-209
Medicare reimbursement for, 206
injection of, 200-202
machine settings for, 203
for myocardial perfusion, 208
patient selection for, 200-202
patients most likely to benefit from, 203
reimbursement for
issues related to, 208-209
stress echocardiography using, 207
timing of, 202-204
transthoracic echocardiography using,
206-207
uses of, 202-204
in left ventricular function assessment,
211-219
automated endocardial border detection in,
213-215
clinical utility of, 212-213
contrast agents in, 212
harmonic imaging, 211-212
and myocardial perfusion, 215-217
in three-dimensional echocardiography, 217
- Contrast pulse sequencing
in low-myocardial infarction detection,
187-189
- Conventional angiography
in pulmonary vascular disease, 375
- Conventional pacing
in atrial fibrillation, 80-83
- Conventional radiography
in pulmonary vascular disease, 375

- Coronary arteriography
 - in cardiac catheterization in pulmonary hypertension, 412
- Coronary artery disease
 - diabetic cardiomyopathy and, 558-559
 - management of, 561
- Coronary artery imaging, 318-321
- Coronary atherosclerosis
 - in diabetes mellitus, **527-540**. See also *Diabetes mellitus, coronary atherosclerosis in*.
- Coronary blood flow reserve
 - reduced
 - implications of, 227-228
- Coronary circulation
 - anatomy of, 221-223
- Coronary microcirculation, **221-231**, 233
 - microbubble contrast agents in, 223
- Coronary stenosis
 - detection of
 - MCE in, **233-251**. See also *Myocardial contrast echocardiography (MCE), in coronary stenosis detection*.
- Coronary syndromes
 - acute
 - MCE in, **253-267**
- Cost-effectiveness
 - of anticoagulation for atrial fibrillation, 56-57
- Cox-Maze III operation
 - for atrial fibrillation, 149-151
- CT. See *Computed tomography (CT)*.
- CTEPH. See *Chronic thromboembolic pulmonary hypertension (CTEPH)*.

D

- Deep venous thrombosis
 - diagnosis of
 - radiography in, 356
- Defibrillator(s)
 - implantable atrioventricular implantable cardioverter, 88-89
- Device therapies
 - for atrial fibrillation, **71-86**, 93-94
 - atrial pacing in
 - suppression of triggers by, 71-74
 - diagnostic features of, 94
 - efficacy of, 93-94

- Diabetes mellitus
 - cardiovascular disease in
 - pathophysiology of
 - endothelial dysfunction in, **505-509**
 - clinical implications of, 507-508
 - future directions in, 507-508
 - mechanisms of, 505-506
 - in metabolic syndrome, 506-507
 - clinical significance of, 527-529
 - coagulation cascade and, 514-515
 - coronary atherosclerosis in, **527-540**
 - anatomic characteristics of, 529-530
 - imaging of
 - prospective studies of
 - need for, 532
 - rationale for, 530-532
 - described, 527
 - in the elderly, **541-546**
 - hypertension in
 - treatment of, 544-546
 - pathophysiologic factors in, 542
 - prevalence of, 541
 - endothelial vasodilator function impairment in, 572
 - epidemiology of, 527-529
 - fibrinolysis in
 - impaired
 - insulin resistance due to, 516-518
 - heart failure and, **553-568**
 - described, 553
 - diabetic cardiomyopathy, 553-559. See also *Diabetic cardiomyopathy*.
 - hyperglycemia, 554
 - insulin resistance and, 556
 - management of, 559-563
 - blood pressure-related, 559-560
 - dyslipidemia-related, 560-561
 - early
 - economic impact of, 562-563
 - glycemic control in, 559
 - microcirculation and, 556-557
 - hypercoagulability associated with, **511-516**
 - clinical implications of, 519
 - therapeutic implications of, 519-521
 - platelet function, coagulopathy, and fibrinolytic system interactions in, **511-526**
 - proteofibrinolytic system within vessel walls in, 518-519
 - type 2
 - cardiovascular diseases and, **485-504**
 - overweight and, 486-491
 - prevalence of, 485
 - cardiovascular health and, 569

- causes of, 494
 - continuing epidemic of, 494
 - defined, 494
 - in the elderly
 - hypertension in, 542-544
 - stroke in, 544
 - future trends in, 496-498
 - heart failure and
 - left ventricular diastolic dysfunction and, 571-572
 - hypertension with
 - arterial stiffness associated with, 573
 - body composition and, 575
 - cardiovascular disease in
 - exercise precautions in, 578-580
 - exercise training effects on, **569-586**
 - fat distribution and, 575
 - relationship between, 569-570
 - systemic inflammation and, 574
 - identification of, 494
 - prevalence of, 494
 - prevention of, 494-495
 - public health implications of, 495-496
 - research perspectives on, 498
 - vessel wall interactions in, 515-516
 - in women, 546-547
- Diabetic cardiomyopathy, 553-559
- coronary artery disease and, 558-559
 - management of, 561
 - diastolic function and, 558
 - functional cardiac abnormalities and, 557-558
 - hyperglycemia and, 554
 - insulin resistance and, 556
 - microcirculation and, 556-557
 - molecular mechanisms of, 555-556
 - pathophysiology of, 553-555
 - systolic function and, 558
- Diastolic function
- diabetic cardiomyopathy and, 558
- Digoxin
- for heart rate control in atrial fibrillation, 37
 - for pulmonary arterial hypertension, 445
- Direct thrombin inhibitors
- for acute pulmonary embolism, 359-360
- Diuretic(s)
- for pulmonary arterial hypertension, 445
- Dobutamine echocardiography
- after acute myocardial infarction
 - vs.* MCE, 262-263
- Dofetilide
- for atrial fibrillation, 23
- Doppler
- pulse inversion
 - in low-myocardial infarction detection, 185
- Drug(s)
- pulmonary arterial hypertension and, 335-336
- Drug delivery
- therapeutic ultrasound for, **301-306**
- Dual chamber detection algorithm
- implantable devices for atrial fibrillation and, 89-92
- Dyslipidemia
- management of, 560-561
- ## E
- ECG. See *Electrocardiography (ECG)*.
- Echocardiography
- in acute pulmonary embolism, 357
 - in chronic pulmonary hypertension, 390-396
 - in chronic thromboembolic pulmonary hypertension, 395
 - contrast. See *Contrast echocardiography*.
 - dobutamine
 - after acute myocardial infarction
 - vs.* MCE, 262-263
 - in mild pulmonary hypertension, 395-396
 - myocardial contrast. See *Myocardial contrast echocardiography (MCE)*.
 - in pulmonary arterial hypertension, 443
 - in pulmonary hypertension, 369, 383-385
 - in pulmonary vascular disease, **383-399**. See also *Pulmonary vascular disease, echocardiography in*.
 - stress
 - using contrast echocardiography, 207
 - three-dimensional
 - contrast use in, 217
 - transesophageal
 - in atrial fibrillation, **115-128**
 - future directions in, 125-126
 - in pulmonary hypertension, 396
 - transthoracic, 115
 - using contrast echocardiography, 206-207
- Elderly
- diabetes mellitus in, **541-546**. See also *Diabetes mellitus, in the elderly*.
 - type 2
 - hypertension in, 542-544
 - insulin resistance in
 - mechanism of, 543

- Electrical cardioversion
 of atrial fibrillation, **103-113**. See also *Atrial fibrillation, electrical cardioversion of*.
- Electrocardiography (ECG)
 in acute pulmonary embolism, 355
- Electrode configuration
 implantable devices for atrial fibrillation and, 92-93
- Embolic disease
 chronic
 pulmonary hypertension due to, 337
- Embolism
 pulmonary. See *Pulmonary embolism*.
- Embolus(i)
 pulmonary
 acute
 echocardiography in, 385-389. See also *Pulmonary embolus, acute, echocardiography in*.
- Endocardial border detection
 automated
 in contrast echocardiography in left ventricular function assessment, 213-215
- Endothelial disease
 molecular markers of, 284
- Endothelial vasodilator function
 exercise and, 573
 impairment of
 in type 2 diabetics with hypertension, 572
- Endothelin receptor antagonists
 for pulmonary arterial hypertension, 445-446
- Endothelium
 microbubble adhesion to
 in absence of targeting ligands, 286-288
- Endothelium-derived factors
 in primary pulmonary hypertension, 424-425
- Exercise
 arterial stiffness and, 573-574
 body composition and, 575-576
 endothelial vasodilator function and, 573
 inflammation and, 574-575
 left ventricular diastolic dysfunction and, 572
 lipoproteins and, 575
- Exercise training
 effects on cardiovascular disease in type 2 diabetics with hypertension, **569-586**
- F**
- Familial pulmonary arterial hypertension, 331-332
- Fibrillation
 atrial. See *Atrial fibrillation*.
- Fibrinolysis
 impaired
 in diabetes mellitus
 insulin resistance due to, 516-518
- Fibrinolytic system
 in diabetes mellitus
 coagulopathy and platelet function
 interactions with, **511-526**
- Flecainide
 for heart rate control in atrial fibrillation, 41
- G**
- Gender
 as factor in atrial fibrillation, 1
- Gene therapy
 delivery of
 therapeutic ultrasound for, **301-306**
 problems associated with, 301-302
- Genetic(s)
 in pulmonary hypertension, 344-345
- Growth factors
 in primary pulmonary hypertension, 424-425
- H**
- Harmonic imaging
 in left ventricular function assessment, 211-212
 in low-myocardial infarction detection, 181-183
- Harmonic power Doppler
 in high-myocardial infarction detection, 194
- Heart
 function of
 abnormalities associated with
 diabetic cardiomyopathy and, 557-558
- Heart failure
 in diabetes mellitus, **553-568**. See also *Diabetes mellitus, heart failure and*.
 management of, 561-562
 in type 2 diabetics
 left ventricular diastolic dysfunction and, 571-572

- Hemangiomatosis
pulmonary capillary
pulmonary arterial hypertension and,
336-337
- Heparin
for acute pulmonary embolism, 358-359
low-molecular-weight
for acute pulmonary embolism, 358-359
- HIV infection. See *Human immunodeficiency virus (HIV) infection*.
- Human immunodeficiency virus (HIV) infection
pulmonary arterial hypertension and, 334-335
- Hypercoagulability
diabetes mellitus-related, **511-516**
clinical implications of, 519
therapeutic implications of, 519-521
- Hyperemia
capillary resistance during, 227-228
myocardial blood flow during
without coronary artery disease
regulation of
viscosity in, 228-229
- Hypertension
in aging diabetic patient, 544-546
in aging type 2 diabetic patient, 542-544
atrial fibrillation and, 6
portal
pulmonary arterial hypertension and,
333-334
pulmonary. See *Pulmonary hypertension*.
- Hypertrophic cardiomyopathy
atrial fibrillation in
antiarrhythmic drug therapy for, 30
MCE in
advantages of, 275
applications of, 277-279
avoidance of nontarget sites with, 276-277
target septal branch identification in,
274-275
- Hypoxia
pulmonary hypertension-related, 337

I

ICU. See *Intensive care unit (ICU)*.

Imaging

- techniques of, **181-197**
technologies in, **181-197**

- Implantable atrioventricular implantable
cardioverter defibrillator, 88-89
- Implantable devices
for atrial fibrillation
future prospects for, **87-101**
- Inflammation
exercise and, 574-575
systemic
in type 2 diabetics with hypertension, 574
- Inotropic stress
vasodilator stress *vs.*, 244-247
- Insulin resistance
in diabetes mellitus
impaired fibrinolysis and, 516-518
diabetic cardiomyopathy and, 556
- Intensive care unit (ICU)
contrast echocardiography
clinical utility of, 212-213
- Interpulse amplitude modulation
in low-myocardial infarction detection,
186-187
- Interpulse phase inversion
in low-myocardial infarction detection,
183-185
- Ischemic cardiomyopathies
chronic
MCE in, **269-282**. See also *Myocardial
contrast echocardiography (MCE)*.
- Ischemic left ventricular dysfunction
chronic
MCE in, 269-270

L

- Left ventricular border
detection of
stress echocardiography using
echocardiographic contrast in, 207
- Left ventricular diastolic dysfunction
exercise and, 572
heart failure in type 2 diabetics due to,
571-572
- Left ventricular dysfunction
chronic ischemic
MCE in, 269-270
- Left ventricular function
assessment of

Left (*continued*)

contrast echocardiography in, **211-219**. See also *Contrast echocardiography, in left ventricular function assessment*.

Lesion(s)

vascular
in pulmonary hypertension, 345-349

Leukocyte(s)

microbubble adhesion to
inflammatory imaging using, 286-288

Lifestyle

modification of
for pulmonary arterial hypertension, 444

Ligand(s)

surface
contrast agent targeting by, 288-294

Lipoprotein(s)

exercise and, 575

Low-molecular-weight heparin

for acute pulmonary embolism, 358-359

M

Magnetic resonance imaging (MRI)

in acute pulmonary embolism, 357
cardiovascular
after acute myocardial infarction
vs. MCE, 264-265
in pulmonary vascular disease, 376

Maze procedure

for atrial fibrillation, 149-151

MCE. See *Myocardial contrast echocardiography (MCE)*.

Medicare reimbursement

for contrast echocardiography, 206

Metabolic syndrome, 491-494

causes of, 492
defined, 491-492
epidemiology of, 492-493
future trends in, 496-498
identification of, 491-492
prevention of, 493-494
research perspectives on, 498

Microbubble(s)

adhered
ultrasonically detected
techniques in, 285-286
adhesion to endothelium
in absence of targeting ligands, 286-288

direct adhesion, 286

adhesion to leukocytes

inflammatory imaging using, 286-288

bolus injections of

myocardial blood flow reserve during
quantification of severity of coronary
stenosis with, 240-243
myocardial blood velocity regional
variations in
assessment of, 239-240

described, 172-173

as target delivering technique without
ultrasound, 304

targeted ultrasound imaging using, **283-299**
basis for, 284-286

contrast agent targeting by surface ligands,
288-294

future challenges in, 294-295

in vivo imaging, 284-285

targeting of angiogenesis markers, 290-292

thrombolysis enhancement using, **301-314**
ultrasound and

thrombolysis enhancement using, 306-312

venous administration of, 243-244

Microbubble contrast agents, 223

for echocardiography, **171-180**

equipment in

design challenges facing, 177-179

reasons for using, 171-172

safety of, 179

ultrasound with, 173-177

Microbubble tracers

properties of, 234

Microcirculation

coronary, **221-231**, 233

microbubble contrast agents in, 223

diabetic cardiomyopathy and, 556-557

Monophasic waveform

studies of

in electrical cardioversion of atrial
fibrillation, 103-104

"Mother rotor" theory

in atrial fibrillation, 15

MRI. See *Magnetic resonance imaging (MRI)*.

Myocardial blood flow

hyperemic

without coronary artery disease

regulation of

viscosity in, 228-229

MCE in quantification of, 234-236

- regulation of
 - myocardial blood volume in, 223-227
 - velocity of
 - quantification of
 - high vs. low mechanical index MCE
 - methods in, 236-238
 - Myocardial blood volume
 - in myocardial blood flow regulation, 223-227
 - Myocardial contrast echocardiography (MCE), 283
 - in acute coronary syndromes, **253-267**
 - in acute myocardial infarction with ST elevation, 255-261
 - after acute myocardial infarction
 - prognostic value of, 261-262
 - vs. cardiovascular MRI, 264-265
 - vs. dobutamine echocardiography, 262-263
 - vs. other imaging techniques, 262-265
 - vs. radionuclide imaging, 263-264
 - in chronic ischemic and nonischemic cardiomyopathies, **269-282**
 - in chronic ischemic left ventricular dysfunction, 269-270
 - in coronary stenosis detection, **233-251**
 - clinical status of, 247-249
 - future directions in, 249
 - described, 253-254
 - in dilated cardiomyopathy, 270-274
 - high vs. low mechanical index methods
 - for quantification of myocardial blood flow velocity, 236-238
 - in hypertrophic cardiomyopathy, 274-279. See also *Hypertrophic cardiomyopathy, MCE in*.
 - quantification of myocardial blood flow with, 234-236
 - ST elevation relevance to, 254-255
 - Myocardial infarction
 - acute
 - infarct size at time of determination of, 255
 - MCE after
 - prognostic value of, 261-262
 - myocardial viability after
 - assessment of, 255-260
 - prediction of
 - MCE in, 261
 - timing of MCE effect on accuracy of, 260-261
 - with ST elevation, 253-254
 - MCE in, 255-261
 - high
 - detection of
 - real-time registration during, 196
 - techniques in, 191-195
 - dual-frame triggers, 195-196
 - harmonic power Doppler, 194
 - multiple triggers, 195-196
 - power Doppler, 193
 - single-frame triggers, 195-196
 - ultraharmonic power Doppler, 194-195
 - low
 - detection of
 - techniques in
 - alternate line phase, 185-186
 - contrast pulse sequencing, 187-189
 - harmonic imaging, 181-183
 - imaging, 181-189
 - interpulse amplitude modulation, 186-187
 - interpulse phase inversion, 183-185
 - nonlinear fundamental, 186
 - pulse inversion Doppler, 185
 - replenishment imaging, 189-191
 - medium
 - detection of
 - techniques in, 191
 - Myocardial perfusion
 - assessment of
 - contrast echocardiography in, 208, 215-217
-
- ## N
- Nondestructive triggered imaging
 - in medium-myocardial infarction detection, 191
 - Nonischemic cardiomyopathies
 - chronic
 - MCE in, **269-282**. See also *Myocardial contrast echocardiography (MCE)*.
 - Nonlinear fundamental techniques
 - in low-myocardial infarction detection, 186
 - Nonlinear oscillations regime, 174
 - Nuclear medicine
 - in pulmonary embolism, 378
 - in pulmonary vascular disease, 376
-
- ## O
- Obesity, 486-491
 - causes of, 487-489
 - continuing epidemic of, 489
 - defined, 486
 - described, 486-487

Obesity (*continued*)

- identification of, 486-487
- prevalence of, 489
- prevention programs related to, 490-491
- public health implications of, 489-490
- visceral
 - cardiovascular risk factors associated with, 543

Overweight, 486-491

- causes of, 487-489
- continuing epidemic of, 489
- defined, 486
- described, 486-487
- identification of, 486-487
- prevalence of, 489
- prevention programs related to, 490-491
- public health implications of, 489-490

Oxygen

- for pulmonary arterial hypertension, 444

P

PAS. See *Pulmonary arterial sarcoma (PAS)*.

Perfusion defects

- stress-induced, 238-239

Persistent pulmonary hypertension of newborn (PPHN)

- pulmonary arterial hypertension and, 337

PID. See *Pulse inversion Doppler (PID)*.

Plaque

- pathoanatomy of, 315

Platelet(s)

- diabetes mellitus effects on, 514

Platelet function

- in diabetes mellitus
 - coagulopathy and fibrinolytic system interactions with, 511-526

Portal hypertension

- pulmonary arterial hypertension and, 333-334

Power Doppler imaging

- in high-myocardial infarction detection, 193

Power modulation

- in low-myocardial infarction detection, 186-187

Power pulse inversion

- in low-myocardial infarction detection, 187-189

PPHN. See *Persistent pulmonary hypertension of newborn (PPHN)*.

Pregnancy

- atrial fibrillation during
 - antiarrhythmic drug therapy for, 29

Primary pulmonary hypertension

- bone morphogenic protein receptor type II gene mutations in, 421-422
- development of
 - molecular mechanisms in, 419-425
 - endothelium-derived factors in, 424-425
- 5-HTR in, 422-424
- 5-HTT in, 422-424
- growth factors in, 424-425
- molecular biology of, 417-429
- molecular derangement in, 417-418
- pathologic derangements in, 417-418
- pulmonary arterial wall remodeling in, 419-420
- pulmonary vascular remodeling in, 420-421
- pulmonary vasoconstriction in, 419

Propafenone

- for heart rate control in atrial fibrillation, 41

Prostacyclin(s)

- for pulmonary arterial hypertension, 446-448

Proteofibrinolytic system

- within vessel walls
 - in diabetes mellitus, 518-519

Pulmonary angiography

- in cardiac catheterization in pulmonary hypertension, 405-408
- in CTEPF diagnosis, 458

Pulmonary angioscopy

- in cardiac catheterization in pulmonary hypertension, 408-412

Pulmonary arterial hypertension, 329-337, 441-452

- classification of
 - WHO, 441-442
- congenital heart disease and, 333
- connective tissue disease and, 332-333
- described, 441
- diagnosis of, 442-444
 - echocardiography in, 395, 443
 - functional assessment in, 443-444
 - right-heart catheterization in, 443
- drug-related, 335-336
- familial, 331-332
- HIV infection and, 334-335
- portal hypertension and, 333-334

- PPHN and, 337
- pulmonary capillary hemangiomatosis and, 336-337
- pulmonary veno-occlusive disease and, 336
- radiology of, 379
- sporadic, 329-331
- toxin-related, 335-336
- treatment of, 444-449
- calcium-channel blockers in, 445
 - digoxin in, 445
 - diuretics in, 445
 - echocardiography in, 395
 - endothelin receptor antagonists in, 445-446
 - experimental therapies in, 448-449
 - lifestyle modification in, 444
 - oxygen in, 444
 - prostacyclins in, 446-448
 - sequence of, 445
 - sildenafil in, 448-449
 - sitaxsentan in, 448
 - supportive therapies in, 444-445
 - surgical, 449
 - viagra in, 448-449
 - warfarin in, 444-445
- Pulmonary arterial sarcoma (PAS), 431-435**
- cell of origin of, 434-435
 - characteristics of, 431-432
 - clinical manifestations of, 432
 - differential diagnosis of, 434
 - epidemiology of, 432
 - imaging studies of, 432
 - molecular pathogenesis of, 434-435
 - pathologic findings of, 432-434
 - prognostic factors in, 434
 - treatment of, 434
- Pulmonary arterial wall remodeling**
- in primary pulmonary hypertension, 419-420
- Pulmonary arteriography**
- in acute pulmonary embolism diagnosis, 356-357
- Pulmonary arteriovenous malformation**
- radiology of, 380-381
- Pulmonary artery(ies)**
- primary sarcomas of, 431-435. See also *Pulmonary arterial sarcoma (PAS)*.
- Pulmonary artery smooth muscle cells**
- inhibited apoptosis in, 420-421
- Pulmonary capillary hemangiomatosis, 436-437**
- pulmonary arterial hypertension and, 336-337
- Pulmonary embolism, 367-373**
- acute, **353-365**
 - clinical manifestations of, 354
 - described, 353
 - diagnosis of, 354-357
 - blood tests in, 355
 - chest radiography in, 355-356
 - ECG in, 355
 - echocardiography in, 357
 - MRI in, 357
 - pulmonary arteriography in, 356-357
 - spiral CT in, 357
 - ventilation-perfusion scan in, 356
 - historical background of, 353
 - incidence of, 353
 - pathophysiology of, 353-354
 - prevention of, 362
 - prognosis of, 362
 - treatment of, 357-362
 - direct thrombin inhibitors in, 359-360
 - heparin in, 358-359
 - thrombolytic agents in, 361
 - vena cava interruption in, 360-361
 - unstable hemodynamics in
 - management of, 361-362
 - classification of, 367
 - clinical presentation of, 367-369
 - defined, 367
 - described, 353
 - diagnosis of, 368-371
 - echocardiography in, 369
 - pulmonary function tests in, 369-370
 - right-heart catheterization in, 371
 - ventilation-perfusion scan in, 370-371
 - radiology of, 377-379
 - suspect
 - diagnosis of, 369
- Pulmonary embolus**
 - acute
 - echocardiography in, 385-389
 - transesophageal
 - typical findings on, 387
 - uses of, 389
 - transthoracic
 - recommendations for, 389
 - typical findings on, 385-387
 - uses of, 387-389
 - Pulmonary function tests**
 - in CTEPH, 456
 - in pulmonary hypertension, 369-370
 - Pulmonary hypertension**
 - arterial, 329-337. See also *Pulmonary arterial hypertension*.

Pulmonary (continued)

- cardiac catheterization in
 - considerations for, 401
 - coronary arteriography in, 412
 - indications for, 401
 - pulmonary angiography in, 405-408
 - pulmonary angioscopy in, 408-412
 - right-heart catheterization, 402-403
 - safety considerations with, 401-402
 - techniques for, **401-415**
 - vasodilator challenge response in catheterization laboratory, 403-405
- chronic
 - differential diagnosis of, 393-395
 - echocardiography in, 390-396
 - features of, 390-393
 - inferior vena cava on, 390-391
 - interventricular septum on, 391-393
 - left-heart chambers on, 391-393
 - pericardium on, 393
 - right-heart chambers on, 390-391
 - tricuspid valve on, 390
 - prognosis of echocardiography in, 395
 - treatment of echocardiography in, 395
- chronic embolic disease and, 337
- chronic thromboembolic echocardiography in, 395
- chronic thrombotic disease and, 337
- classification of, **327-341**
 - WHO, 327, 329
- diseases associated with, 344-345
- echocardiographic measurements in, 383-385
 - in estimation of pulmonary arterial pressure by Bernoulli equation, 384-385
 - in right ventricular function, 383
 - in right ventricular volume measurement, 383
 - in tricuspid regurgitation, 383-384
- echocardiography in
 - transesophageal, 396
- epidemiology of, **327-341**
 - Evian, 327-328
- genetic susceptibility for, 344-345
- historical background of, 327
- hypoxia-related, 337
- mild echocardiography in, 395-396
- pathology of, **343-351**
- primary
 - molecular biology of, **417-429**. See also *Primary pulmonary hypertension*.

respiratory system disorders and, 337

severe

- hemodynamics in, 343-344
- vascular lesions in, 345-349

venous, 337

Pulmonary thromboendarterectomy

- for CTEPF, 460-463
- for CTEPH, **467-478**. See also *Chronic thromboembolic pulmonary hypertension (CTEPH)*, *pulmonary thromboendarterectomy surgery for*.

Pulmonary vascular disease

- echocardiography in, **383-399**
 - acute pulmonary embolus, 385-389
 - pulmonary hypertension, 383-385
- evaluation of
 - modalities in, 375-376
- radiology of, **375-382**
 - conventional angiography, 375
 - conventional radiography, 375
 - CT, 375-376
 - MRI, 376
 - nuclear medicine, 376
 - pulmonary arterial disease, 379
 - pulmonary arteriovenous malformation, 380-381
 - pulmonary embolism, 377-379
 - pulmonary veno-occlusive disease, 379-380
 - pulmonary venous hypertension, 376-377

Pulmonary vascular remodeling

- in primary pulmonary hypertension, 420-421

Pulmonary vasculature

- described, 431
- tumors of, **1-10**
 - primary involvement, 431-437
 - pulmonary arterial sarcoma, 431-435
 - pulmonary capillary hemangiomatosis, 436-437
 - pulmonary venous sarcoma, 435-436
 - secondary involvement, 437-438

Pulmonary vasoconstriction

- in primary pulmonary hypertension, 419

Pulmonary veins

- in atrial fibrillation, 15-18

Pulmonary veno-occlusive disease

- pulmonary arterial hypertension and, 336
- radiology of, 379-380

Pulmonary venous hypertension, 337

- radiology of, 376-377

Pulmonary venous sarcoma (PVS), 435-436

- characteristics of, 435
- clinical manifestations of, 435
- epidemiology of, 435
- imaging studies of, 435
- pathologic findings in, 435-436
- prognosis of, 436
- treatment of, 436

Pulse inversion

- in low-myocardial infarction detection, 183-185

Pulse inversion Doppler (PID)

- in low-myocardial infarction detection, 185

PVS. See *Pulmonary venous sarcoma (PVS)*.

Q**Quality of life**

- implantable devices for atrial fibrillation effects on, 98

R**Radiography**

- chest. See *Chest radiography*.
- in deep venous thrombosis, 356

Radiology

- of pulmonary vascular disease, 375-382. See also *Pulmonary vascular disease, radiology of*.

Radionuclide imaging

- after acute myocardial infarction
- vs. CME, 263-264

Real-time registration

- during high-myocardial infarction detection, 196

Replenishment imaging

- in low-myocardial infarction detection, 189-191

Respiratory system disorders

- pulmonary hypertension-related, 337

Right-heart catheterization

- in CTEPF diagnosis, 458
- in pulmonary arterial hypertension diagnosis, 443
- in pulmonary hypertension diagnosis, 371

S**Safety issues**

- in cardiac catheterization in pulmonary hypertension, 401-402

Sarcoma(s)

- pulmonary arterial, 431-435. See also *Pulmonary arterial sarcoma (PAS)*.
- pulmonary venous, 435-436. See also *Pulmonary venous sarcoma (PVS)*.

Seasonality

- as factor in atrial fibrillation, 3

Sildenafil

- for pulmonary arterial hypertension, 448-449

Sinus rhythm

- maintenance of
- determinants of success of, 36
- restoration of
- anticoagulation and, 57

Sitaxsentan

- for pulmonary arterial hypertension, 448

Sotalol

- for atrial fibrillation, 22-23
- for heart rate control in atrial fibrillation, 41
- in prevention of postoperative atrial fibrillation, 162-163

Sporadic pulmonary arterial hypertension,

329-331

ST elevation

- acute myocardial infarction with, 253-254
- MCE in, 255-261
- pathophysiology of, 254-255
- relevance to MCE, 254-255

Stand-alone implantable atrial defibrillator, 88**Stenosis(es)**

- coronary
- detection of
- MCE in, 233-251. See also *Myocardial contrast echocardiography (MCE)*, in *coronary stenosis detection*.

Stress

- perfusion defects due to, 238-239
- vasodilator vs. inotropic, 244-247

Stress echocardiography

- using contrast echocardiography, 207

Stroke

- in aging type 2 diabetic patient, 544
- atrial flutter-related
- risk factors for, 58
- prevention of
- in atrial fibrillation
- efficacy of, 47-50

- Surface ligands
 - contrast agent targeting by, 288-294
- Systolic function
 - diabetic cardiomyopathy and, 558

T

- Three-dimensional echocardiography
 - contrast use in, 217
- Thromboendarterectomy
 - pulmonary
 - for CTEPF, 460-463
- Thrombolytic agents
 - for acute pulmonary embolism, 361
- Thrombotic disease
 - chronic
 - pulmonary hypertension due to, 337
- Thrombus-targeted imaging, 293-294
- Toxin(s)
 - pulmonary arterial hypertension and, 335-336
- Transesophageal echocardiography
 - in atrial fibrillation, **115-128**
 - future of, 125-126
 - described, 115-120
- Transesophageal echocardiography-guided cardioversion, 121-125
- Transthoracic echocardiography, 115
 - using contrast echocardiography, 206-207
- Tricuspid regurgitation
 - echocardiographic measurements in, 383-384
- Triggered replenishment imaging
 - in medium-myocardial infarction detection, 191
- Tumor(s)
 - of pulmonary vasculature, **1-10**. See also *Pulmonary vasculature, tumors of*.

U

- Ultraharmonic power Doppler
 - in high-myocardial infarction detection, 194-195
- Ultrasound
 - for drug and gene delivery, **301-306**
 - for gene therapy delivery, **301-306**
 - microbubble interaction with, 173-177
 - microbubbles and
 - thrombolysis enhancement using, 306-312
 - thrombolysis enhancement using, **301-314**
 - optimization of, 305-306

V

- Vascular imaging
 - contrast agents for, **315-322**
- Vascular lesions
 - in pulmonary hypertension, 345-349
- Vasoconstriction
 - pulmonary
 - in primary pulmonary hypertension, 419
- Vasodilator stress
 - inotropic stress *vs.*, 244-247
- Vaughn-Williams class II -adrenergic receptor antagonists
 - in prevention of postoperative atrial fibrillation, 162
- Vaughn-Williams class III antiarrhythmic sotalol and amiodarone
 - in prevention of postoperative atrial fibrillation, 162-163
- Vein(s)
 - pulmonary
 - in atrial fibrillation, 15-18
- Vena cava interruption
 - in acute pulmonary embolism management, 360-361
- Ventilation-perfusion scan
 - in acute pulmonary embolism diagnosis, 356
 - in CTEPF diagnosis, 457
 - in pulmonary hypertension diagnosis, 370-371
- Viagra
 - for pulmonary arterial hypertension, 448-449

W

- Warfarin
 - for pulmonary arterial hypertension, 444-445
- Waveform(s)
 - biphasic
 - studies of
 - in electrical cardioversion of atrial fibrillation, 104-105
 - in electrical cardioversion of atrial fibrillation, 103-105
 - monophasic
 - studies of
 - in electrical cardioversion of atrial fibrillation, 104-105
- Wavelet(s)
 - in atrial fibrillation, 13-15
- Women
 - diabetes mellitus in, 546-547

